HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Carlos Besses Selected Research

anagrelide (Agrylin)

1/2018Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study.
4/2014Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.
11/2012Pharmacokinetics and tolerability of anagrelide hydrochloride in young (18 - 50 years) and elderly (≥ 65 years) patients with essential thrombocythemia.
6/2009[Retrospective analysis of the efficacy and tolerability of anagrelide in patients with essential thrombocytemia: Spanish registry of essential thrombocytemia].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Carlos Besses Research Topics

Disease

10Essential Thrombocythemia
01/2018 - 06/2009
9Neoplasms (Cancer)
01/2021 - 10/2005
9Thrombosis (Thrombus)
05/2019 - 07/2009
6Hemorrhage
01/2018 - 08/2010
5Polycythemia Vera
01/2017 - 11/2012
4Primary Myelofibrosis (Myelosclerosis)
01/2021 - 11/2012
3Thrombocytopenia (Thrombopenia)
12/2017 - 08/2007
2Splenomegaly
01/2016 - 07/2014
2Venous Thrombosis (Deep-Vein Thrombosis)
01/2016 - 08/2010
2Marginal Zone B-Cell Lymphoma (MALT Lymphoma)
08/2008 - 10/2005
2Lymphoma (Lymphomas)
08/2008 - 10/2005
1Adenocarcinoma
03/2020
1Disease Progression
03/2019
1Fibrosis (Cirrhosis)
11/2018
1Hyperplasia
11/2018
1Leukemia
01/2018
1Leukopenia
12/2017
1Anemia
12/2017
1Myocardial Infarction
01/2013
1Heart Failure
01/2013
1Refractory Anemia
07/2012
1Thrombocytosis (Thrombocythemia)
07/2012
1Non-Hodgkin Lymphoma (Lymphosarcoma)
06/2011
1Myeloproliferative Disorders (Myeloproliferative Disorder)
07/2009
1Crohn Disease (Crohn's Disease)
08/2007
1Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
10/2005

Drug/Important Bio-Agent (IBA)

5Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
05/2019 - 06/2013
4anagrelide (Agrylin)FDA LinkGeneric
01/2018 - 06/2009
4Hydroxyurea (Hydrea)FDA LinkGeneric
01/2017 - 09/2013
3Janus Kinase 2IBA
03/2020 - 07/2012
3Syntex adjuvant formulationIBA
12/2017 - 11/2012
2DNA (Deoxyribonucleic Acid)IBA
01/2021 - 01/2020
2ruxolitinibIBA
03/2020 - 01/2016
2Reticulin (Reticular Fiber)IBA
11/2018 - 07/2014
2insulin receptor-related receptor (IRR)IBA
05/2014 - 08/2010
1Cell-Free Nucleic AcidsIBA
01/2021
1Janus Kinase InhibitorsIBA
01/2016
1Janus Kinase 1IBA
01/2016
1Coloring Agents (Dyes)IBA
07/2014
1L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
07/2014
1diethylstilbestrol monophosphate (PDES)IBA
01/2013
1Hemoglobins (Hemoglobin)IBA
11/2012
1Biomarkers (Surrogate Marker)IBA
06/2011
1pro-brain natriuretic peptide (1-76)IBA
06/2011
1Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA
08/2010
1ABO Blood-Group SystemIBA
07/2009
1Infliximab (Remicade)FDA Link
08/2007
1Adalimumab (Humira)FDA Link
08/2007
1Rituximab (Mabthera)FDA Link
10/2005
1GemcitabineFDA Link
10/2005

Therapy/Procedure

15Therapeutics
05/2019 - 08/2010
3Drug Therapy (Chemotherapy)
06/2011 - 10/2005
2Erythrocyte Transfusion
12/2017 - 01/2017